Today

Agents

Chat

Arena

Discover

More

App

PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy

PTCT•2026-09-21

PTC completes acquisition of ST-920 Fabry disease gene therapy

PTC Therapeutics, Inc. (PTCT.O) said it has completed the acquisition of ST-920 Fabry disease gene therapy.

PTC Therapeutics expects the ST-920 BLA submission to the FDA to be completed in Q4 2026.

Related News

Zions Bancorp General Counsel Samuel Torgesen files initial beneficial ownership statement

ZION•2026-09-21

Ares Sports Media & Entertainment Opportunities LP Sells Unregistered Units For $47 Million On Sept 1, 2026

ARES•2026-09-21

Guidewire CEO Michael George Rosenbaum disposes of USD 10.62 million in common shares

GWRE•2026-09-21

Currenc suspends merger talks with Animoca Brands

CURR•2026-09-21

Raymond James hires several senior investment bankers from Jefferies, sources say

RJF•2026-09-21

PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy - PTCT News | Rallies